Danuglipron: Why Pfizer Discontinued Its Oral GLP-1 Pill

Danuglipron (development code PF-06882961) was Pfizer's bet on an oral, small-molecule GLP-1 receptor agonist — a once- or twice-daily pill, not an injection, that could compete with semaglutide and tirzepatide. The science worked in the sense that danuglipron really did cause meaningful weight loss in trials. The problem was everything around it: a twice-daily formulation with a discontinuation rate so high that Pfizer dropped it, then a once-daily reformulation that Pfizer halted entirely in April 2025 after a single trial participant showed signs of potential drug-induced liver injury. This is a discontinuation story, not a how-to. It matters because danuglipron is a clean case study in the bar an oral small-molecule GLP-1 has to clear — tolerability and safety, not just efficacy — and that bar is exactly why orforglipron (Lilly) and oral semaglutide (Rybelsus) are the oral GLP-1s that actually reached patients.

The honest summary

• Danuglipron is dead as a weight-loss drug. On April 14, 2025, Pfizer announced it was discontinuing development of danuglipron for chronic weight management. There is no path to an approved danuglipron product for obesity; this article exists to explain what happened, not how to obtain it.
• It was an oral small-molecule GLP-1 agonist. Unlike injectable peptides (semaglutide, tirzepatide) and unlike the peptide pill Rybelsus, danuglipron (PF-06882961) was a non-peptide small molecule designed to activate the GLP-1 receptor when swallowed as a tablet (Saxena 2021 Nat Med^[6]).
• The efficacy was real. In a phase 2b obesity trial, twice-daily danuglipron produced placebo-adjusted weight reductions of up to roughly −13% at the top dose over 26–32 weeks (Buckeridge 2025 Diabetes Obes Metab^[1]). The molecule worked.
• The tolerability did not. In that same trial only 39.3% of participants completed treatment; about 38% discontinued because of adverse events, driven by nausea and vomiting that worsened at higher doses. Pfizer dropped the twice-daily formulation in late 2023 on the strength of that signal (Buckeridge 2025^[1]).
• The once-daily pivot was killed by a liver signal. Pfizer reformulated to once-daily dosing, met its pharmacokinetic goals, then discontinued the whole program in April 2025 after a single asymptomatic participant in a dose-optimization study showed potential drug-induced liver injury that resolved after stopping the drug.
• The lesson is the bar for oral GLP-1s. Danuglipron shows that an oral small-molecule GLP-1 has to clear a tolerability and safety bar, not just an efficacy one. That is the context for why orforglipron and oral semaglutide matter — they are the oral GLP-1s that cleared it.

What danuglipron actually was

Danuglipron is a small-molecule GLP-1 receptor agonist. That phrase carries the whole story. The approved GLP-1 drugs — semaglutide, liraglutide, tirzepatide — are peptides: large, fragile chains of amino acids that the gut digests, which is why almost all of them are injected. Even Rybelsus, the one oral peptide, is semaglutide wrapped in an absorption enhancer (SNAC) and still absorbs erratically. A small molecule is different: a compact, drug-like chemical that survives the stomach, absorbs predictably, and can be manufactured and packaged like an ordinary pill. If you could make a small molecule that switched on the GLP-1 receptor, you would have an oral obesity drug with the manufacturing economics and patient convenience of a statin. That was danuglipron's entire promise (Saxena 2021 Nat Med^[6]).

Pfizer developed danuglipron first for type 2 diabetes and then for obesity. Early-phase work established that the molecule lowered blood glucose and was orally active: a multiple-ascending-dose phase 1 trial in type 2 diabetes (Saxena 2021 Nat Med^[6]) and a phase 2 glycemic-control trial (Saxena 2023 JAMA Netw Open^[5]) confirmed the pharmacology, while a separate phase 2 study compared dose-escalation schemes specifically to manage the gastrointestinal side effects that came with it (Saxena 2023 Diabetes Obes Metab^[4]). The diabetes data were encouraging enough to justify a full obesity program.

What the obesity trial actually showed

The pivotal read on danuglipron in obesity is the phase 2b dose-ranging trial published as Buckeridge 2025 in Diabetes, Obesity and Metabolism^[1] (ClinicalTrials.gov NCT04707313). It randomized 628 adults with obesity and without diabetes to twice-daily danuglipron or placebo for 26 or 32 weeks, with danuglipron escalated to doses of 40–200 mg twice daily over 1-, 2-, or 4-week intervals. The primary endpoint was percent change in body weight.

On efficacy, danuglipron delivered. Every dose group beat placebo with statistically significant weight loss, and the least-squares mean placebo-adjusted reduction ranged from about −5.0% at the low end to about −12.9% at the top dose. A double-digit percent weight loss from an oral small molecule is a genuine result — it put danuglipron in the conversation with the injectables on efficacy alone.

It is worth being precise about why this matters. A weight-loss drug that half the people quit is not a weight-loss drug that works in the real world, because the average exposure — and therefore the average weight lost — collapses once you account for everyone who stopped. High discontinuation also concentrates the benefit in the minority who tolerate the drug, which is not a population you can build a mass-market obesity product around. The twice-daily dosing schedule, which kept gut exposure high around the clock, was widely seen as the culprit, which is why Pfizer pivoted to a once-daily formulation rather than abandoning the molecule outright.

Why Pfizer killed it: the once-daily liver signal

Pfizer reformulated danuglipron into a modified-release, once-daily version, aiming to smooth out the peak drug levels thought to drive the nausea and the dropout. By early 2025 the company reported that its dose-optimization studies of the once-daily formulation had met their key pharmacokinetic objectives and identified a dose and formulation it believed could deliver competitive efficacy and tolerability in phase 3. On the numbers it had set out to hit, the reformulation was working.

Then came the safety signal. On April 14, 2025, Pfizer announced it was discontinuing development of danuglipron for chronic weight management. According to Pfizer's statement, the overall rate of liver-enzyme elevations across a safety database of more than 1,400 participants was in line with approved drugs in the class — but a single asymptomatic participant in one of the dose-optimization studies experienced a case of potential drug-induced liver injury, which resolved after the participant stopped taking danuglipron. Weighing that finding against the broader landscape, Pfizer concluded danuglipron's risk–benefit profile did not support taking it into phase 3, and ended the program.

A note on hepatotoxicity context: a single resolved, asymptomatic case in one study is not proof that danuglipron causes liver injury at a population level, and Pfizer was explicit that the broader liver-enzyme data looked class-typical. But in obesity — a setting where the drug is taken by tens of millions of otherwise-healthy people for years — the tolerance for an unexplained liver signal is extremely low. A drug-induced-liver-injury question that might be acceptable in, say, an oncology setting is often disqualifying for a chronic, elective, mass-market obesity therapy. That asymmetry is why one case was enough to end a multi-year program.

How its weight loss compared to the approved drugs

On paper, danuglipron's top-dose ~13% placebo-adjusted weight loss was in the neighborhood of semaglutide's STEP-1 result (−14.9% at 68 weeks, Wilding 2021^[2]) and short of tirzepatide's SURMOUNT-1 top dose (−20.9% at 72 weeks, Jastreboff 2022^[3]). But this comparison flatters danuglipron in two ways worth stating plainly. First, the timepoints differ: danuglipron's number came at 26–32 weeks while the injectables' came at 68–72, so danuglipron was measured earlier on its curve. Second, and more important, the injectable numbers are intention-to-treat figures from trials with normal retention, whereas danuglipron's efficacy was achieved in a trial that lost 60% of its participants. The honest summary is that danuglipron had competitive efficacy and uncompetitive deliverability — and a drug has to have both.

What danuglipron means for the oral GLP-1 race

Danuglipron's collapse did not kill the oral small-molecule GLP-1 idea; it defined the standard it has to meet. The category survives in two forms that cleared the bar danuglipron could not. Oral semaglutide (Rybelsus, and an investigational higher-dose oral version) is the peptide-in-a-pill approach — proven, but with absorption and dosing constraints. Orforglipron (Lilly's small molecule, branded Foundayo) is the more direct heir to danuglipron's thesis: a non-peptide oral GLP-1 that has advanced through late-stage obesity and diabetes trials without the discontinuation and liver problems that ended danuglipron. The contrast is the point. Danuglipron and orforglipron set out to do the same thing; one tripped over tolerability and a safety signal, the other has not, and that difference is the entire story of which oral GLP-1s reach patients.

For anyone researching danuglipron in 2026, the practical bottom line is simple: it is not a drug you can get, because it is not a drug anymore. Pfizer ended the program. The prescribable options remain the approved injectables — semaglutide (Wegovy/Ozempic) and tirzepatide (Zepbound/Mounjaro) — and the oral GLP-1s that actually cleared development. Anything sold as “danuglipron” through research-peptide or gray-market channels is, by definition, outside any approved supply chain for a compound its own developer judged unsafe enough to abandon.